Rakovina Unveils New CNS-Penetrating ATR Inhibitor Data
Rakovina Therapeutics will present new preclinical data on a series of AI-designed ATR inhibitors with central nervous system penetrance...
Rezolute Reveals Plans for Upcoming Investor Conferences
Rezolute plans a concentrated investor relations push this fall, with management set to meet investors at the Maxim Growth...
Minovia Drug MNV-201 Receives FDA Orphan Drug Designation
Minovia Therapeutics has secured FDA Orphan Drug Designation for MNV-201 in myelodysplastic syndromes, adding to the asset’s existing Fast...
Tafenoquine Shows Promise in First Babesiosis Patient Study
60 Degrees Pharmaceuticals reported the first negative post-treatment result in its expanded access study of tafenoquine for relapsing babesiosis...
Regeneron Spotlights Oncology Advances for Tough Cancers
Regeneron will present seven oncology abstracts at ESMO 2025, led by new Phase 3 C-POST safety and pharmacokinetic data...
Bexorg’s Revolutionary AI Platform for CNS gets $42.5M
Bexorg has closed a $23 million Series A led by Engine Ventures, bringing total funding to $42.5 million to...
Biodesix Announcing New Presentations, Events at CHEST 2025
Biodesix will present interim real-world data from the Clarify study at the 2025 CHEST Annual Meeting in Chicago, including...
argenx to Highlight Immunology Data at 2025 AANEM & MGFA
Argenx is using the AANEM Annual Meeting and MGFA Scientific Session to widen the runway for its neuromuscular franchise....
BioCryst’s Surging HAE Focus With Astria Therapeutics Deal
BioCryst Pharmaceuticals is acquiring Astria Therapeutics in a cash-and-stock deal valuing Astria at an implied $13.00 per share, or...
Assembly Biosciences to Present at Investor Conference
Assembly Biosciences will host fireside chats at two investor forums: the H.C. Wainwright Liver Disease Virtual Conference on October...